Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta‐analysis of randomized controlled trials

OBJECTIVE We aimed to investigate the effect of targeted therapies on cardiovascular risk in psoriasis (PsO) and psoriatic arthritis (PsA) via a meta-analysis of randomized controlled trials (RCTs). METHODS Pubmed, Embase, Cochrane Library, and Scopus were searched for RCTs reporting targeted therapies in patients with PsO/PsA published until 28 October 2021. The primary and secondary outcomes included the relationship between targeted therapies and all cardiovascular events (CVEs), major adverse cardiovascular events (MACEs), myocardial infarction (MI), heart failure, and stroke in PsO/PsA. The outcome risk ratios (RRs) were calculated using the Mantel-Haenszel fixed-effect method. RESULTS A total of 81 articles involving 88 RCTs were included. There was no statistically significant difference regarding the occurrence of all CVEs for all targeted therapies (RR = 1.03, 95% CI 0.74-1.43, P = .85) compared to placebo in PsO/PsA. No statistically significant difference existed between drugs and placebo in patients with PsA on all CVEs (RR = 0.81, 95% CI 0.48-1.36, P = .43). Surprisingly, the incidence of all CVEs was higher in the low dosage group compared to the high dosage group of all targeted therapies (RR = 1.97, 95% CI 1.19-3.27, P = .008) and prominently anti-interleukin-17 agent (RR = 2.20, 95% CI 1.05-4.58, P = .04). CONCLUSION Current targeted therapies are not associated with the risk of CVEs. Based on the existing evidence, we reported here that a dosage reduction of targeted therapies was not recommended.

[1]  M. Schirmer,et al.  Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A Cross-Sectional Study , 2022, Frontiers in Medicine.

[2]  E. D. De Jong,et al.  Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study , 2021, Trials.

[3]  G. Kitas,et al.  Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction , 2021, Journal of inflammation research.

[4]  L. Iversen,et al.  Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi‐centre cohort study , 2021, Journal of internal medicine.

[5]  H. Nakagawa,et al.  Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study , 2021, Dermatology and Therapy.

[6]  L. Coates,et al.  GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting , 2021, The Journal of Rheumatology. Supplement.

[7]  W. Tillett,et al.  Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 , 2020, Annals of the Rheumatic Diseases.

[8]  L. Coates,et al.  Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial , 2020, Annals of the Rheumatic Diseases.

[9]  E. Oger,et al.  Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. , 2020, JAMA dermatology.

[10]  J. Primdahl,et al.  EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update , 2020, Annals of the Rheumatic Diseases.

[11]  M. Gooderham,et al.  Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis , 2020, JAMA dermatology.

[12]  M. Ohtsuki,et al.  Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial , 2019, The Journal of dermatology.

[13]  W. Koenig,et al.  Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. , 2019, The Journal of investigative dermatology.

[14]  G. Fabbrocini,et al.  Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows , 2018, Front. Immunol..

[15]  R. Buchbinder,et al.  Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study , 2018, Arthritis Research & Therapy.

[16]  M. Lebwohl,et al.  Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double‐blind, etanercept‐ and placebo‐controlled study (CIMPACT) , 2018, Journal of the American Academy of Dermatology.

[17]  A. Gottlieb,et al.  Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2) , 2018, Journal of the American Academy of Dermatology.

[18]  A. Gottlieb,et al.  Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis , 2018, The British journal of dermatology.

[19]  C. Edwards,et al.  Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial , 2018, Rheumatology.

[20]  D. M. van der Heijde,et al.  Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study , 2018, Annals of the rheumatic diseases.

[21]  P. Rahman,et al.  Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) , 2018, Arthritis Research & Therapy.

[22]  J. Walsh,et al.  Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) , 2018, Annals of the rheumatic diseases.

[23]  B. Elewski,et al.  Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo‐controlled trial , 2018, Journal of the American Academy of Dermatology.

[24]  A. Kavanaugh,et al.  Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis , 2017, Arthritis & rheumatology.

[25]  M. Chimenti,et al.  A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors , 2017, Clinical Rheumatology.

[26]  N. Mehta,et al.  Psoriasis as a human model of disease to study inflammatory atherogenesis. , 2017, American journal of physiology. Heart and circulatory physiology.

[27]  A. Kimball,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial , 2017, Journal of the American Academy of Dermatology.

[28]  A. Armstrong,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA , 2017, Journal of the American Academy of Dermatology.

[29]  M. Gooderham,et al.  The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE) , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  D. Gladman,et al.  Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 , 2016, Annals of the rheumatic diseases.

[31]  G. Wang,et al.  Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  A. Gottlieb,et al.  Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial , 2017, Journal of the American Academy of Dermatology.

[33]  M. Cutolo,et al.  A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial , 2016, The Journal of Rheumatology.

[34]  A. Gottlieb,et al.  A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis , 2016, The British journal of dermatology.

[35]  Zheng-Sheng Yang,et al.  The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis , 2016, Clinical Reviews in Allergy & Immunology.

[36]  C. Edwards,et al.  Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) , 2016, Annals of the rheumatic diseases.

[37]  W. Boehncke.  Psoriasis and Psoriatic Arthritis: Flip Sides of the Coin? , 2016, Acta dermato-venereologica.

[38]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[39]  A. Ogdie,et al.  The Epidemiology of Psoriatic Arthritis. , 2015, Rheumatic diseases clinics of North America.

[40]  A. Gottlieb,et al.  Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial , 2015, The British journal of dermatology.

[41]  A. Gottlieb,et al.  Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials , 2015, The British journal of dermatology.

[42]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[43]  C. Paul,et al.  Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  E. Edson-Heredia,et al.  Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[45]  A. Gottlieb,et al.  Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) , 2015, The British journal of dermatology.

[46]  D. Margolis,et al.  Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study , 2014, Annals of the rheumatic diseases.

[47]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[48]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[49]  D. M. van der Heijde,et al.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) , 2013, Annals of the rheumatic diseases.

[50]  A. Kimball,et al.  Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[51]  Baoxi Wang,et al.  Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). , 2013, Journal of drugs in dermatology : JDD.

[52]  K. Papp,et al.  Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study , 2013, The British journal of dermatology.

[53]  Y. Ko,et al.  Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation‐wide study , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[54]  J. Ortonne,et al.  Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study , 2012, The British journal of dermatology.

[55]  D. Symmons,et al.  Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review , 2012, Annals of the rheumatic diseases.

[56]  B. Strober,et al.  Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study , 2012, The British journal of dermatology.

[57]  H. Nakagawa,et al.  Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial , 2012, The Journal of dermatology.

[58]  Jee-ho Choi,et al.  Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). , 2011, Journal of dermatological science.

[59]  L. Skov,et al.  Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study , 2011, Journal of Internal Medicine.

[60]  H. Nakagawa,et al.  Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study , 2010, The Journal of dermatology.

[61]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[62]  T. Luger,et al.  Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial with open‐label extension , 2008, The British journal of dermatology.

[63]  D. Gladman,et al.  Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). , 2008, The Journal of rheumatology.

[64]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[65]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[66]  Jonathan J Deeks,et al.  Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events , 2007, Statistics in medicine.

[67]  D. Gladman,et al.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial , 2006, Annals of the rheumatic diseases.

[68]  B. Miller,et al.  Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. , 2006, Journal of the American Academy of Dermatology.

[69]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[70]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.

[71]  A. Gottlieb,et al.  A randomized trial of etanercept as monotherapy for psoriasis. , 2003, Archives of dermatology.